Theratechnologies presents data at ID Week on tesamorelin

Theratechnologies presented data in a poster session at ID Week 2023 in Boston, Mass., demonstrating that treatment with tesamorelin significantly reduced visceral adipose tissue, VAT, and hepatic fat fraction in people with HIV treated with integrase inhibitor, INSTI, based regimens. In the retrospective sub-analysis, tesamorelin reduced VAT by 8.3% after 12 months of treatment, compared to a 10.8% increase in VAT among placebo-treated patients treated with INSTIs. While anthropometric measurements at baseline did not differ between the two groups, VAT increased in the placebo group even in the absence of significant weight or BMI changes. Furthermore, the tesamorelin group experienced a 31% relative reduction in HFF compared to a 0% reduction for the placebo group at 12 months. “As we learn more about the mechanisms of rapid weight gain and, in particular, visceral fat accumulation in people with HIV who are on integrase inhibitors, potential treatment strategies will become more important,” commented Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “Tesamorelin remains the only FDA-approved therapy to treat excess abdominal fat in adults with HIV, and these data are yet another key piece in highlighting its efficacy in modern HIV management.”